WTS: The Watch the Spot Trial

Sponsor
Kaiser Permanente (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02623712
Collaborator
Patient-Centered Outcomes Research Institute (Other), University of California, Davis (Other), University of California, San Francisco (Other)
35,200
1
2
70.9
496.7

Study Details

Study Description

Brief Summary

This study will compare two clinically accepted protocols for surveillance imaging in individuals who are found to have a small pulmonary nodule on chest computed tomography (CT) scans.

Condition or Disease Intervention/Treatment Phase
  • Other: More Frequent Surveillance Strategy
  • Other: Less Frequent Surveillance Strategy
N/A

Detailed Description

The investigators will conduct an unblinded, prospective, pragmatic, cluster-randomized, comparative effectiveness trial of more intensive versus less intensive CT surveillance of patients found to have small pulmonary nodules in diverse health care settings. The goal of this pragmatic clinical trial is to identify the surveillance strategy that will maximize early diagnosis for individuals with cancerous nodules, while minimizing unnecessary surveillance of patients without cancer that can result in emotional stress, exposure to harmful ionizing radiation, and the discovery of incidental findings that may lead to unnecessary treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
35200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Watch the Spot Trial: A Pragmatic Trial of More Versus Less Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules
Actual Study Start Date :
Mar 6, 2017
Anticipated Primary Completion Date :
Jul 31, 2022
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: More Frequent CT Surveillance

Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)

Other: More Frequent Surveillance Strategy
Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)

Active Comparator: Less Frequent CT Surveillance

Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.

Other: Less Frequent Surveillance Strategy
Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.

Outcome Measures

Primary Outcome Measures

  1. Proportion of cancerous nodules with stage greater than T1a disease by the AJCC staging system, 7th edition [24 months after enrollment]

    Among individuals with small pulmonary nodules identified either incidentally or by screening, compare more versus less intensive surveillance to determine the number of cancerous nodules that progress beyond stage T1a.

Secondary Outcome Measures

  1. Number of days from date of nodule identification to date of cancer diagnosis [Up to 2 years]

    Ongoing, final analysis in year 5

  2. Survival time from date of cancer diagnosis until death or end of study [Up to 4 years]

    Ongoing, final analysis in year 5

  3. Emotional distress, measured with the Impact of Events Scale [Measured at 2 months, 13 months, and 25 months following nodule identification]

    Compare patient-reported emotional distress

  4. Anxiety, measured with the State Anxiety Inventory, 6-item [Measured at 2 months, 13 months, and 25 months following nodule identification]

    Compare patient-reported anxiety

  5. General health status, measured with a single question [Measured at 2 months, 13 months, and 25 months following nodule identification]

    Compare patient-reported general health status

  6. Numbers of imaging tests, biopsy tests and surgical procedures, measured by review of electronic health records [Measured from date of nodule identification until date of cancer diagnosis or completion of 24 months of follow-up]

    Compare resource utilization.

  7. Exposure to ionizing radiation, using the computed tomography dose index (CTDIvol), measured in mGy (milliGray) [Measured from date of nodule identification to date of cancer diagnosis or completion of 24 months of follow-up]

    Compare effective radiation doses received.

  8. Exposure to ionizing radiation, using the the dose length product (DLP), measured in mGy*cm [Measured from date of nodule identification to date of cancer diagnosis or completion of 24 months of follow-up]

    Compare effective radiation doses received.

  9. Numbers of CT scans recommended by the assigned protocol that were not ordered by the ordering provider, and/or not completed by the patient [Measured from date of nodule identification to date of cancer diagnosis or completion of 24 months of follow-up]

    Compare adherence to the recommended protocols for CT surveillance, and adherence to use of low radiation dose techniques.

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

The target population includes adults with small lung nodules that may represent a new diagnosis of lung cancer, who typically would be managed by CT surveillance in usual clinical practice. Thus, we will enroll all patients:

  • aged ≥35 years

  • at least one nodule measuring ≤15 mm in average diameter on chest CT.

Exclusion Criteria:
  • Pregnant Women

  • Age <35 years

  • Known diagnosis of cancer (except non-melanoma skin cancer) within 5 years

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kaiser Permanente Southern California Pasadena California United States 91011

Sponsors and Collaborators

  • Kaiser Permanente
  • Patient-Centered Outcomes Research Institute
  • University of California, Davis
  • University of California, San Francisco

Investigators

  • Principal Investigator: Michael K Gould, MD, MS, Kaiser Permanente School of Medicin

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Michael K Gould, MD, Director for Health Services Research and Implementation Science, Kaiser Permanente
ClinicalTrials.gov Identifier:
NCT02623712
Other Study ID Numbers:
  • 1000001
First Posted:
Dec 8, 2015
Last Update Posted:
Aug 25, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2021